Quest Diagnostics Stock News

One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J. , Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based laboratory testing and treatment of pregnant wo...

Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J. , Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Associ...

BALTIMORE, Md. and MONTREAL , July 29, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal's affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology's personalized MRD technology (Haystack MRD™) to evaluate tr...

Quest Diagnostics: Beat Down After Beating Q2 Estimates

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J.

Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Michael Cherny - Leerink Patrick Donnelly - Citi Da...

Quest Diagnostics raised its 2024 profit and revenue forecasts on Tuesday, banking on robust demand for its health tests.

Second quarter revenues of $2.40 billion, up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2% from 2023 Full year 2024 revenues now expected to be between $9.50 billion and $9.58 billion; reported diluted EPS now expected to be between $7.57 and $7.77; and adjusted diluted EPS expected to be betwe...